Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2020.3864DOI Listing

Publication Analysis

Top Keywords

immunocryosurgery basal
4
basal cell
4
cell carcinoma
4
carcinoma impact
4
impact circulating
4
circulating cd4
4
cd4 cd25
4
cd25 t regulatory
4
t regulatory cells
4
cells serum
4

Similar Publications

Article Synopsis
  • Monitoring skin cancer treatment is difficult, and confirming tumor presence after treatment is crucial for spotting relapses early.
  • Optical coherence tomography (OCT) offers a non-invasive way to image skin lesions like basal cell carcinomas but struggles with image quality due to light scattering and observer subjectivity.
  • This study presents a new method using advanced image processing techniques to improve OCT image resolution and accurately differentiate between tumor tissue and scar tissue after cryosurgery.
View Article and Find Full Text PDF

Application of a burn scar assessment tool for the evaluation of visual scarring following immunocryosurgery for facial basal cell carcinoma.

Eur J Dermatol

November 2022

Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, University Campus, GR-45110 Ioannina, Greece.

Background: The therapeutic interventions for basal cell carcinoma (BCC) impact facial cosmesis.

Objectives: Our aim was to assess the aesthetic burden of facial BCC treatment by evaluating the extent of the tumour site visually based on clinical images before and after immunocryosurgery; a minimally invasive combination treatment of topical imiquimod and cryosurgery.

Materials & Methods: A three-item (texture, height, colour) burn scar scale was independently applied by four physicians (two dermatologists and two plastic surgeons) on archival semi-standardized clinical images of facial BCC before and one year after immunocryosurgery.

View Article and Find Full Text PDF

In this retrospective, chart review study, we evaluated the feasibility of immunocryosurgery in facial, non-superficial basal cell carcinomas (BCC) that had relapsed after standard surgery. Inclusion criteria were (a) 'biopsy confirmed relapse of facial BCC', (b) known 'calendar year of surgical excision(s)', and (c) 'relapse within 10 years after the last surgical excision'. Tumors treated from 1 January 2011 to 31 December 2020 with a standard 5-week immunocryosurgery cycle (daily imiquimod application for 5 weeks and a cryosurgery session at day 14) were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!